Qiagen N.V.

NYSE:QGEN 주식 리포트

시가총액: US$8.7b

Qiagen 배당 및 자사주 매입

배당 기준 점검 2/6

Qiagen 은(는) 현재 수익률이 6.24% 인 배당금 지급 회사입니다.

핵심 정보

6.2%

배당 수익률

6.0%

자사주 매입 수익률

총 주주 수익률12.2%
미래 배당 수익률0.5%
배당 성장률n/a
다음 배당 지급일n/a
배당락일n/a
주당 배당금n/a
배당 성향0%

최근 배당 및 자사주 매입 업데이트

Recent updates

내러티브 업데이트 • Aug 07

QGEN: Post Pandemic Testing And Takeover Interest Will Shape Oncology And Diagnostics Outlook

Qiagen's analyst price target has been revised higher to $45.28 from $43.96 as analysts factor in updated Q2 commentary, mixed but generally higher Street targets in the $36 to $48 range, and modest adjustments to growth and profitability assumptions. Analyst Commentary Recent Street research on Qiagen points to a mix of optimism and caution.
내러티브 업데이트 • Jul 23

QGEN: Takeover Interest Will Drive Reassessment Of Core Life Science Franchise

Qiagen's updated analyst price target has moved lower from about $55.91 to $49.47, reflecting mixed Street research. Several firms trimmed targets on QuantiFERON uncertainty, while others maintained Hold or moved to more positive stances, citing a solid life science franchise and potential growth inflection.
Seeking Alpha • Jul 12

Qiagen: New Launches Signal A Turnaround

Summary Qiagen N.V. is rated a Buy, supported by new product launches and automation initiatives poised to drive revenue growth. QGEN's QIAspirant Connect and partnerships like Inpeco/Diasorin and NVIDIA AI collaboration are expected to offset sluggish QuantiFERON demand and accelerate sales. Management reaffirms 1–2% CER sales growth for FY2026, with new launches already receiving orders and broad market access in sample preparation. QGEN trades at a discount to peers on P/S multiples, yet demonstrates higher forward growth potential, reinforcing bullish upside momentum. Read the full article on Seeking Alpha
내러티브 업데이트 • Jul 09

QGEN: Reset Expectations And Product Pipeline Will Shape Medium Term Outlook

Analysts now place Qiagen's fair value at $36, down from $38. This reflects a reset in expectations around QuantiFERON growth and recent price target reductions, which offset more constructive views on the stock's longer term positioning and valuation.
내러티브 업데이트 • Jun 25

QGEN: Expect Post Pandemic Testing Demand To Support Oncology And Diagnostics Expansion

Analysts have adjusted the fair value estimate for Qiagen slightly higher to $43.96 from $43.82, reflecting a modestly higher discount rate, alongside mixed recent price target moves that highlight both concerns over growth in areas like QuantiFERON and renewed interest in the stock as a potential structural beneficiary of post pandemic demand trends. Analyst Commentary Recent Street research on Qiagen reflects a split view, with some bullish analysts pointing to potential growth opportunities and valuation support, while more cautious analysts focus on execution risks and reduced expectations in key product areas.
분석 기사 • Jun 21

Qiagen (QGEN) Stock Could Be 15.7% Undervalued After QIAcuity Expansion

Qiagen (NYSE:QGEN) is in focus after announcing new additions to its QIAcuity digital PCR ecosystem, including expanded gene expression tools, higher multiplexing and upgraded software and automation for high throughput labs. See our latest analysis for Qiagen. The QIAcuity update comes as Qiagen’s share price has shown mixed momentum, with a 1-month share price return of 5.06%, a year-to-date share price return that is down 22.32%, and a 5-year total shareholder return that is down 23.67%...
내러티브 업데이트 • Jun 06

QGEN: Expect Balance Sheet Strength To Support Oncology And Diagnostics Expansion Beyond Current Headwinds

Qiagen's updated analyst price target has been reduced by about $9.70. This reflects analysts' lower growth and profitability assumptions after recent cuts across the Street tied to softer QuantiFERON trends and a rebased full year outlook.
새로운 내러티브 • May 15

Latent TB Testing Expansion And Automation Will Support Stronger Long Term Prospects

Catalysts About Qiagen Qiagen provides molecular diagnostics, sample preparation and bioinformatics tools used in clinical testing and research. What are the underlying business or industry changes driving this perspective?
새로운 내러티브 • Apr 30

Latent Tuberculosis And Research Pressures Will Constrain Progress Yet Long-Term Prospects Remain Intact

Catalysts About Qiagen Qiagen provides sample preparation, diagnostic testing and bioinformatics tools for molecular and clinical laboratories. What are the underlying business or industry changes driving this perspective?
내러티브 업데이트 • Apr 29

QGEN: Expect Balance Sheet Strength To Support Oncology And Diagnostic Platform Expansion

Qiagen's analyst price target has been adjusted modestly lower to $53.53 from $55.46 as analysts factor in a slightly higher discount rate, a marginally different profit margin outlook, and recent target cuts and rating changes across major banks, alongside some upward revisions earlier in the period. Analyst Commentary Recent research shows a mix of optimism and caution around Qiagen, with several firms adjusting price targets in both directions and a few making rating changes.
내러티브 업데이트 • Apr 10

QGEN: I Expect Balance Sheet Strength To Drive Future Shareholder Returns

Qiagen's analyst price target is updated to $55.46. The modest change reflects mixed but generally constructive research commentary that cites an undemanding valuation, a robust balance sheet, and steady recent shareholder returns as key supports.
내러티브 업데이트 • Mar 27

QGEN: Possible Sale Prospects Are Expected To Drive Future Returns

The analyst price target for Qiagen has been nudged higher to $55.46 from $55.23, as analysts cite an undemanding valuation, a robust balance sheet, and a track record of average annual shareholder returns of 13% as key supports for the updated view. Analyst Commentary Recent research on Qiagen presents a mix of optimism and caution, with several firms adjusting ratings and price targets while focusing on valuation, balance sheet strength, and execution risk.
내러티브 업데이트 • Mar 12

QGEN: Possible Sale And Margin Upside Are Expected To Drive Future Returns

The Analyst Price Target on Qiagen has increased by $2, with analysts citing improved profit margin assumptions and a slightly lower future P/E multiple, while they refine discount rate and revenue growth inputs. Analyst Commentary Bullish and bearish analysts are split on Qiagen, with several firms lifting price targets while others trim estimates or ratings.
내러티브 업데이트 • Feb 25

QGEN: Possible Sale And Fresh Takeover Interest Will Drive Future Upside

Analysts have raised their blended price target for Qiagen by about $0.63 to $55.23. This reflects updated views on slightly different revenue growth, profit margin and future P/E assumptions after a mix of recent target increases and reductions across the Street.
내러티브 업데이트 • Feb 11

QGEN: Fairly Valued Outlook Will Hinge On Possible Sale And Execution Risks

Qiagen's analyst price target has edged up by about $1 to roughly $55, as analysts factor in slightly higher fair value and profit margin assumptions, along with a modest adjustment to growth expectations and P/E multiples. Analyst Commentary Recent Street research on Qiagen has been active, with several firms adjusting price targets in both directions and a few issuing downgrades.
내러티브 업데이트 • Jan 28

QGEN: Fairly Valued Outlook Will Depend On Possible Sale And Leadership Transition

Analysts have slightly raised their Qiagen price target to about $53.32 from $53.23, reflecting small tweaks to revenue growth, discount rate, profit margin, and future P/E assumptions following recent downgrades in Street research. Analyst Commentary Bullish Takeaways Bullish analysts see the updated price target of about US$53.32 as still supported by long term earnings potential, even after recent revisions to revenue growth and profit margin assumptions.
내러티브 업데이트 • Jan 08

QGEN: Fairly Valued Outlook Will Rely On Leadership Transition And Acquisitions

Narrative Update on Qiagen Analysts have lifted their Qiagen fair value estimate from approximately €50.43 to about €53.23, citing updated assumptions around revenue growth, profit margins and the P/E multiple applied to future earnings. What's in the News Qiagen plans a stock split or significant stock dividend with a 1 to 1.05263 ratio effective January 8, 2026, which adjusts the number of shares while keeping overall value aligned with the split terms (Key Developments).
분석 기사 • Jan 07

An Intrinsic Calculation For Qiagen N.V. (NYSE:QGEN) Suggests It's 21% Undervalued

Key Insights The projected fair value for Qiagen is US$59.66 based on 2 Stage Free Cash Flow to Equity Qiagen is...
내러티브 업데이트 • Dec 14

QGEN: Stable End Markets Will Support Gradual Sentiment Recovery Ahead

Analysts have trimmed their price target on Qiagen slightly, with a modest fair value reduction of about $0.36 per share. They cite still stable end markets, expectations for gradual improvement ahead, and a view that investment sentiment and valuations have largely bottomed.
내러티브 업데이트 • Nov 29

QGEN: Gradual Improvement Ahead As End Markets Remain Stable And Sentiment Bottoms

Analysts have modestly lowered their price target for Qiagen from $55 to $53 per share, citing stable end markets and expectations of gradual improvement ahead. Analyst Commentary Analysts have provided a balanced view of Qiagen's current outlook, highlighting both opportunities and ongoing challenges as the company navigates a gradually improving market environment.
내러티브 업데이트 • Nov 15

QGEN: Improving Sentiment And Stable Markets Will Set Stage For Future Upside

Analysts have slightly lowered their price target for Qiagen, reducing it by approximately $0.86 to reflect stable end markets. They also acknowledge that improvement is expected as investment sentiment stabilizes.
분석 기사 • Nov 08

Earnings Beat: Qiagen N.V. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Shareholders might have noticed that Qiagen N.V. ( NYSE:QGEN ) filed its quarterly result this time last week. The...
내러티브 업데이트 • Oct 31

QGEN: Future Results Will Depend On Automation And Gradual Sentiment Recovery

Analysts have slightly lowered their price target for Qiagen from $55 to $53, citing stable end markets and anticipated gradual improvements in investment sentiment. Analyst Commentary Recent analyst updates highlight a nuanced outlook for Qiagen, with attention drawn to both its strengths and areas of potential risk in the near term.
내러티브 업데이트 • Oct 17

Syndromic Diagnostics And Automation Will Shape Future Healthcare

Analysts have slightly lowered their price target for Qiagen, reflecting a small decrease from $51.79 to $51.64 per share. They cite ongoing stability in end markets and expectations for gradual valuation improvement.
내러티브 업데이트 • Oct 03

Syndromic Diagnostics And Automation Will Shape Future Healthcare

Analysts have slightly reduced their fair value and price targets for Qiagen, with the consensus moving from approximately $52.39 to $51.79. This change is attributed to stabilizing end markets and expectations of gradual improvement in industry conditions.
내러티브 업데이트 • Sep 04

Syndromic Diagnostics And Automation Will Shape Future Healthcare

Analysts remain cautiously optimistic on Qiagen, citing modest macroeconomic improvements and solid company execution despite persistent sector headwinds, resulting in an unchanged consensus price target of $52.39. Analyst Commentary Bullish analysts cite modest improvements in macroeconomic conditions, including easing tariff concerns, as supportive of Qiagen's shares.
분석 기사 • Sep 02

Qiagen's (NYSE:QGEN) Strong Earnings Are Of Good Quality

Qiagen N.V.'s ( NYSE:QGEN ) earnings announcement last week was disappointing for investors, despite the decent profit...

지급의 안정성과 성장

배당 데이터 가져오는 중

안정적인 배당: 배당금 지급이 안정적인 반면, QGEN 은(는) 배당금을 지급한 지 10년도 채 되지 않았습니다.

배당금 증가: QGEN 의 배당금 지급이 증가했지만 회사는 2 년 동안만 배당금을 지급했습니다.

배당 수익률 vs 시장

Qiagen 배당 수익률 vs 시장
QGEN의 배당 수익률은 시장과 어떻게 비교되나요?
구분배당 수익률
회사 (QGEN)6.2%
시장 하위 25% (US)1.3%
시장 상위 25% (US)4.0%
업계 평균 (Life Sciences)0.6%
분석가 예측 (QGEN) (최대 3년)0.5%

주목할만한 배당금: QGEN 의 배당금( 6.24% )은 US 시장에서 배당금 지급자의 하위 25%( 1.31% )보다 높습니다.

고배당: QGEN 의 배당금( 6.24% )은 US 시장( 4% )

주주 대상 이익 배당

수익 보장: QGEN 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.

주주 현금 배당

현금 흐름 범위: 현금 지급 비율 ( 123.9% )이 높기 때문에 QGEN 의 배당금 지급은 현금 흐름으로 잘 충당되지 않습니다.

높은 배당을 제공하는 우량 기업 찾기

7D

1Y

7D

1Y

7D

1Y

기업 분석 및 재무 데이터 상태

데이터최종 업데이트 (UTC 시간)
기업 분석2026/08/09 03:45
종가2026/08/07 00:00
수익2026/06/30
연간 수익2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지데이터기간미국 소스 예시 *
기업 재무제표10년
  • 손익계산서
  • 현금흐름표
  • 대차대조표
분석가 컨센서스 추정치+3년
  • 재무 예측
  • 분석가 목표주가
시장 가격30년
  • 주가
  • 배당, 분할 및 기타 조치
지분 구조10년
  • 주요 주주
  • 내부자 거래
경영진10년
  • 리더십 팀
  • 이사회
주요 개발10년
  • 회사 공시

* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Qiagen N.V.는 42명의 분석가가 다루고 있습니다. 이 중 16명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가기관
Robert BambergerBaird
Catherine Ramsey SchulteBaird
Charles ButlerBarclays